High-density lipoprotein in Alzheimer's disease: From potential biomarkers to therapeutics.

Abstract

The inverse correlation between high-density lipoprotein (HDL) levels in vivo and the risk of Alzheimer's disease (AD) has become an inspiration for HDL-inspired AD therapy, including plain HDL and various intelligent HDL-based drug delivery systems. In this review, we will focus on the two endogenous HDL subtypes in the central nervous system (CNS), apolipoprotein E-based HDL (apoE-HDL) and apolipoprotein A-I-based HDL (apoA-I-HDL), especially their influence on AD pathophysiology to reveal HDL's potential as biomarkers for risk prediction, and summarize the relevant therapeutic mechanisms to propose possible treatment strategies. We will emphasize the latest advances of HDL as therapeutics (plain HDL and HDL-based drug delivery systems) to discuss the potential for AD therapy and review innovative techniques in the preparation of HDL-based nanoplatforms to provide a basis for the rational design and future development of anti-AD drugs.

• Authors: Yi Jin, Kudzai Chifodya, Guochen Han, Wenxin Jiang, Yun Chen, Yang Shi, Qiao Xu, Yilong Xi, Jun Wang, Jianping Zhou, Huaqing Zhang, Yang Ding
• Journal: Journal of controlled release : official journal of the Controlled Release Society (J Control Release) Vol. 338 Pg. 56-70 (10 10 2021) ISSN: 1873-4995 [Electronic] Netherlands
• PMID: 34391838 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2021 Elsevier B.V. All rights reserved.

Chemical References

• Apolipoprotein A-I
• Apolipoproteins E
• Biomarkers
• Lipoproteins, HDL

Topics

• Alzheimer Disease (drug therapy)
• Apolipoprotein A-I
• Apolipoproteins E
• Biomarkers
• Humans
• Lipoproteins, HDL